Literature DB >> 25680402

Welfarism versus extra-welfarism: can the choice of economic evaluation approach impact on the adoption decisions recommended by economic evaluation studies?

James Buchanan1, Sarah Wordsworth.   

Abstract

A long-running debate surrounds the equivalence of the welfarist and extra-welfarist approaches to economic evaluation. There is a growing belief that the extra-welfarist approach may not necessarily provide all the information that decisionmakers require in certain contexts, e.g. evaluation of complex interventions. As the number of these interventions being evaluated increases, it is crucial that the most appropriate economic evaluation approach is used to enable decisionmakers to be confident in their adoption decisions. We conducted a literature review to evaluate the potential for the choice of economic evaluation approach to impact on the adoption decisions recommended by economic evaluation studies. We found that for every five studies applying both approaches, one shows limited or no concordance in economic evaluation results: the different approaches suggest conflicting adoption decisions, and there is no pattern to which approach provides the most convincing adoption evidence. Only one study in ten indicates which results will best inform adoption decisions. We conclude that the choice of approach can significantly impact on the adoption decisions recommended by economic evaluation studies, with conflicting results creating confusion over whether or not interventions provide good value for money. Health economists rarely provide sufficient guidance to decisionmakers to alleviate this confusion.

Entities:  

Mesh:

Year:  2015        PMID: 25680402     DOI: 10.1007/s40273-015-0261-3

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  36 in total

Review 1.  Conditions for the near equivalence of cost-effectiveness and cost-benefit analyses.

Authors:  Mohan V Bala; Gary A Zarkin; Josephine A Mauskopf
Journal:  Value Health       Date:  2002 Jul-Aug       Impact factor: 5.725

2.  Valuing the economic benefits of complex interventions: when maximising health is not sufficient.

Authors:  Katherine Payne; Marion McAllister; Linda M Davies
Journal:  Health Econ       Date:  2012-02-06       Impact factor: 3.046

3.  A causal modelling approach to the development of theory-based behaviour change programmes for trial evaluation.

Authors:  Wendy Hardeman; Stephen Sutton; Simon Griffin; Marie Johnston; Anthony White; Nicholas J Wareham; Ann Louise Kinmonth
Journal:  Health Educ Res       Date:  2005-03-21

4.  Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs.

Authors:  M Brisson; W J Edmunds
Journal:  Med Decis Making       Date:  2006 Sep-Oct       Impact factor: 2.583

Review 5.  Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis.

Authors:  Scott D Grosse; Sarah Wordsworth; Katherine Payne
Journal:  Genet Med       Date:  2008-09       Impact factor: 8.822

6.  Should we invest in environmental interventions to encourage physical activity in England? An economic appraisal.

Authors:  Sophie J Beale; Matthew W Bending; Paul Trueman; Bhash Naidoo
Journal:  Eur J Public Health       Date:  2012-02-24       Impact factor: 3.367

7.  Economics of coronary artery bypass grafting.

Authors:  A Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-03

8.  Smoke alarm giveaway and installation programs: an economic evaluation.

Authors:  Ying Liu; Karin A Mack; Shane T Diekman
Journal:  Am J Prev Med       Date:  2012-10       Impact factor: 5.043

9.  Economic evaluation of oral sumatriptan compared with oral caffeine/ergotamine for migraine.

Authors:  K W Evans; J A Boan; J L Evans; A Shuaib
Journal:  Pharmacoeconomics       Date:  1997-11       Impact factor: 4.981

10.  The costs and benefits of deep brain stimulation surgery for patients with dystonia: an initial exploration.

Authors:  John Yianni; Alexander L Green; Emma McIntosh; Richard G Bittar; Carol Joint; Richard Scott; Ralph Gregory; Peter G Bain; Tipu Z Aziz
Journal:  Neuromodulation       Date:  2005-07
View more
  8 in total

1.  Incorporating Quantitative Patient Preference Data into Healthcare Decision Making Processes: Is HTA Falling Behind?

Authors:  David John Mott
Journal:  Patient       Date:  2018-06       Impact factor: 3.883

Review 2.  A Review of Health Economic Studies Comparing Traditional and Massively Parallel Sequencing Diagnostic Pathways for Suspected Genetic Disorders.

Authors:  Patrick Fahr; James Buchanan; Sarah Wordsworth
Journal:  Pharmacoeconomics       Date:  2020-02       Impact factor: 4.981

3.  Cost-Benefit and Cost-Utility Analyses to Demonstrate the Potential Value-for-Money of Supermarket Shelf Tags Promoting Healthier Packaged Products in Australia.

Authors:  Jaithri Ananthapavan; Gary Sacks; Liliana Orellana; Josephine Marshall; Ella Robinson; Marj Moodie; Miranda Blake; Amy Brown; Rob Carter; Adrian J Cameron
Journal:  Nutrients       Date:  2022-05-03       Impact factor: 6.706

Review 4.  Cost-effectiveness analyses of genetic and genomic diagnostic tests.

Authors:  Katherine Payne; Sean P Gavan; Stuart J Wright; Alexander J Thompson
Journal:  Nat Rev Genet       Date:  2018-01-22       Impact factor: 53.242

Review 5.  Conceptualising 'Benefits Beyond Health' in the Context of the Quality-Adjusted Life-Year: A Critical Interpretive Synthesis.

Authors:  Lidia Engel; Stirling Bryan; David G T Whitehurst
Journal:  Pharmacoeconomics       Date:  2021-08-23       Impact factor: 4.981

6.  Patients' Preferences for Genomic Diagnostic Testing in Chronic Lymphocytic Leukaemia: A Discrete Choice Experiment.

Authors:  James Buchanan; Sarah Wordsworth; Anna Schuh
Journal:  Patient       Date:  2016-12       Impact factor: 3.883

7.  Economic evidence for the prevention and treatment of atopic eczema: a protocol for a systematic review.

Authors:  Tracey Helen Sach; Emma McManus; Christopher Mcmonagle; Nick Levell
Journal:  Syst Rev       Date:  2016-05-27

Review 8.  Aspects and Challenges of Resource Use Measurement in Health Economics: Towards a Comprehensive Measurement Framework.

Authors:  Luca M M Janssen; Ruben M W A Drost; Aggie T G Paulus; Kirsty Garfield; William Hollingworth; Sian Noble; Joanna C Thorn; Irina Pokhilenko; Silvia M A A Evers
Journal:  Pharmacoeconomics       Date:  2021-06-25       Impact factor: 4.981

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.